The Aims and Measures section is intended to provide protocol users with a menu of measures for multiple purposes that may include the following:

- population health improvement measures,
- quality improvement measures for delivery systems,
- measures from regulatory organizations such as Joint Commission,
- measures that are currently required for public reporting,
- measures that are part of Center for Medicare Services Physician Quality Reporting initiative, and
- other measures from local and national organizations aimed at measuring population health and improvement of care delivery.

This section provides resources, strategies and measurement for use in closing the gap between current clinical practice and the recommendations set forth in the guideline.

The subdivision of this section is:

- Aims and Measures
Aims and Measures

1. Increase the percentage of patients with or at high risk for atherosclerotic disease that are on statin therapy.

Measures for accomplishing this aim:

a. Percentage of patients ≤ 75 years of age who have clinical ASCVD and are prescribed statin therapy.

   Exclusion: Patients for whom there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.

b. Percentage of patients ≥ 21 years of age with primary LDL-C ≥ 190 mg/dL who are prescribed statin therapy.

   Exclusion: Patients for whom there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.

c. Percentage of patients ages 40 to 75 years without a history of CVD who have one or more risk factors (e.g., dyslipidemia, diabetes, hypertension, smoking) and a calculated 10-year CVD event risk of 10% or greater and are prescribed statin therapy.

   Exclusion: Patients for whom there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.
Measurement Specifications

Measurement #1a
Percentage of patients ≤ 75 years of age who have clinical ASCVD and are prescribed statin therapy.

Population Definition
Patients ≤ 75 years of age who have clinical ASCVD. Exclusion: Patients for which there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.

Data of Interest
\[
\frac{\text{# of patients prescribed statin therapy}}{\text{# of patients} \leq 75 \text{ years of age who have clinical ASCVD}}
\]

Numerator/Denominator Definitions
Numerator: Number of patients who are prescribed statin therapy. See ACC/AHA definitions for statin definitions.
Denominator: Number of patients ≤ 75 years of age who have clinical ASCVD.
Exclusion: Patients for whom there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.

Method/Source of Data Collection
Review EHR for patients meeting criteria in the denominator and determine the number of patients meeting the numerator criteria.

Time Frame Pertaining to Data Collection
Monthly.

Notes
This is a process measure, and improvement is noted as an increase in the rate.
Measurement #1b

Percentage of patients ≥ 21 years of age with primary LDL-C ≥ 190 mg/dL who are prescribed statin therapy.

Population Definition

Patients ≥ 21 years of age with primary LDL-C ≥ 190 mg/dL.

Exclusion: Patients for whom there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.

Data of Interest

\[
\frac{\text{# of patients prescribed statin therapy}}{\text{# of patients} \geq 21 \text{ years of age with primary LDL-C} \geq 190 \text{ mg/dL}}
\]

Numerator/Denominator Definitions

Numerator: Number of patients who are prescribed statin therapy. See ACC/AHA definitions for statin definitions.

Denominator: Number of patients ≥ 21 years of age with primary LDL-C ≥ 190 mg/dL.

Exclusion: Patients for whom there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.

Method/Source of Data Collection

Review EHR for patients meeting criteria in the denominator and determine the number of patients meeting the numerator criteria.

Time Frame Pertaining to Data Collection

Monthly.

Notes

This is a process measure, and improvement is noted as an increase in the rate.
Measurement #1c

Percentage of patients ages 40 to 75 years without a history of CVD who have one or more risk factors (e.g., dyslipidemia, diabetes, hypertension, smoking) and a calculated 10-year CVD event risk of 10% or greater and are prescribed statin therapy.

Population Definition

Patients ages 40 to 75 years without a history of CVD who have one or more risk factors (e.g., dyslipidemia, diabetes, hypertension, smoking) and a calculated 10-year CVD event risk of 10% or greater.

Exclusion: Patients for whom there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.

Data of Interest

<table>
<thead>
<tr>
<th># of patients prescribed statin therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td># of patients ages 40 to 75 years without a history of CVD who have one or more risk factors (e.g., dyslipidemia, diabetes, hypertension, smoking) and a calculated 10-year CVD event risk of 10% or greater</td>
</tr>
</tbody>
</table>

Numerator/Denominator Definitions

Numerator: Number of patients who are prescribed statin therapy.

Denominator: Number of patients aged 40 to 75 years without a history of CVD who have one or more risk factors (dyslipidemia, diabetes, hypertension, smoking) and a calculated 10-year CVD event risk of 10% or greater.

Exclusion: Patients for whom there is documentation that statin therapy is contraindicated or not tolerated, including those who are pregnant or at risk for pregnancy.

Method/Source of Data Collection

Review EHR for patients meeting criteria in the denominator and determine the number of patients meeting the numerator criteria.

Time Frame Pertaining to Data Collection

Monthly.

Notes

This is a process measure, and improvement is noted as an increase in the rate.